Pfizer dumps Exubera

The New York-based pharmaceutical company, Pfizer, has dumped the sale of inhaled powder insulin product Exubera, recombinant human insulin with particle diameter between 1 and 5 mm, from the market after 11 years of development and one full year of sales. According to analysts, the main reasons for dumping the drug is that the firm is struggling to replace Lipitor and the company did not contact Nektar Therapeutics, the partner and product originator, before issuing the news. The reason for dumping of the drug is due to poor sales in the first 9 months of the introduction. Various reasons for poor sales of drug are the company was ill-prepared to launch the product in the first place; poor job marketing and they did not court the nurses and certified diabetic educators regarding the use of the drug.